Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses

(177)Lu-iPSMA is a novel radioligand developed at ININ-Mexico with a high affinity for the PSMA protein heavily expressed in cancer cells of approximately 95% of patients with metastatic castration-resistant prostate cancer (mCRPC). (177)Lu-DOTATOC is a patent-free radioligand, molecularly recognize...

Descripción completa

Detalles Bibliográficos
Autores principales: Luna-Gutiérrez, Myrna, Hernández-Ramírez, Rodrigo, Soto-Abundiz, Airam, García-Pérez, Osvaldo, Ancira-Cortez, Alejandra, López-Buenrostro, Sergio, Gibbens-Bandala, Brenda, Soldevilla-Gallardo, Irma, Lara-Almazán, Nancy, Rojas-Pérez, Melissa, Ocampo-García, Blanca, Azorín-Vega, Erika, Santos-Cuevas, Clara, Ferro-Flores, Guillermina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386094/
https://www.ncbi.nlm.nih.gov/pubmed/37514174
http://dx.doi.org/10.3390/pharmaceutics15071988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386094/
https://www.ncbi.nlm.nih.gov/pubmed/37514174
http://dx.doi.org/10.3390/pharmaceutics15071988

Ejemplares similares